Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;31(1):42-6.
doi: 10.1016/j.kjms.2014.10.004. Epub 2014 Dec 2.

Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy

Qi-Jun Wan  1 , Hao-Fei Hu  1 , Yong-Cheng He  2 , Shao-Dong Luan  1 , Hong-Tao Chen  1 , Hong-Ping Liu  1 , Tong Li  1 , Yi Xu  1 , Hui-Li Xu  1 , Ying Liao  1
Affiliations

Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy

Qi-Jun Wan et al. Kaohsiung J Med Sci. 2015 Jan.

Abstract

The tolerance of mycophenolate mofetil (MMF; Shanghai Roche, China) in Lee Classes III, IV, and V immunoglobulin A nephropathy (IgAN) remains unclear. This article reports nine cases of severe pneumonia (SP), including pneumocystis pneumonia (PCP) and cytomegalovirus (CMV) pneumonia, and its risk factors in MMF plus low-dose corticosteroid-treated patients with Lee Classes III, IV, and V IgAN. Fifty-three patients with IgAN were included in this single-center study. The treatment regimen was MMF (1-1.5 g/d) plus low-dose corticosteroids (0.5 mg/kg/d). SP was defined as diffuse bilateral lung infiltrate with respiratory failure. PCP was diagnosed by detecting the organisms in the sputum and bronchoalveolar lavage. CMV infection was diagnosed through serum screening for CMV-IgG and IgM antibodies and CMV-DNA testing by a real-time polymerase chain reaction assay. The risk factors of SP were analyzed. Nine cases (16.9%) of SP occurred in this study. All SP developed at approximately the 10(th)-14(th) week after the initiation of the regimen: PCP was diagnosed in four cases and CMV infection in two cases. Renal function impairing was more serious in patients with SP than in those without SP, as evidenced by estimated glomerular filtration rate (p = 0.019) and serum creatinine level (p = 0.016). Six of the nine SPs occurred in MMP plus low-dose methylprednisolone group, which was statistically higher than that in the MMF plus low-dose prednisone group (p = 0.000). The incidence of SP in this study was 16.9%. Chronically impaired renal function and the use of methylprednisolone may be the risk factors for SP.

Keywords: Cytomegalovirus; IgA nephropathy; Mycophenolate mofetil; Pneumocystis pneumonia; Severe pneumonia.

PubMed Disclaimer

References

    1. Danovitch G.M.. Mycophenolate mofetil: a decade of clinical experience. Transplantation. 2005; 80: S272–S274. - PubMed
    1. Tang S., Leung J.C., Chan L.Y., Lui Y.H., Tang C.S., Kan C.H., et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005; 68: 802–812. - PubMed
    1. Xu G., Tu W., Jiang D., Xu C.. Mycophenolate mofetil treatment for IgA nephropathy: a meta‐analysis. Am J Nephrol. 2009; 29: 362–367. - PubMed
    1. Azevedo L.S., Castro M.C., Paula F.J., Ianhez L.E., David‐Neto E.. Mycophenolate mofetil may protect against pneumocystis carinii pneumonia in renal transplanted patients. Rev Inst Med Trop Sao Paulo. 2005; 47: 143–145. - PubMed
    1. Lv J., Zhang H., Cui Z., Su T., Zhang Y., Wang H.. Delayed severe pneumonia in mycophenolate mofetil‐treated patients with IgA nephropathy. Nephrol Dial Transplant. 2008; 23: 2868–2872. - PubMed

MeSH terms